Reuters logo
BRIEF- SymBio Pharmaceuticals commences phase III clinical trial for TREAKISYM
August 31, 2017 / 7:06 AM / 4 months ago

BRIEF- SymBio Pharmaceuticals commences phase III clinical trial for TREAKISYM

Aug 31(Reuters) - SymBio Pharmaceuticals Ltd

* Says it initiated a phase 3 study of the anticancer drug TREAKISYM® for the indication of relapsed/refractory diffuse large B-cell lymphoma

Source text in Japanese:goo.gl/ftLXxp

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below